IT1270993B - ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS - Google Patents

ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS

Info

Publication number
IT1270993B
IT1270993B ITMI940506A ITMI940506A IT1270993B IT 1270993 B IT1270993 B IT 1270993B IT MI940506 A ITMI940506 A IT MI940506A IT MI940506 A ITMI940506 A IT MI940506A IT 1270993 B IT1270993 B IT 1270993B
Authority
IT
Italy
Prior art keywords
derivatives
quinzolylaminic
antagonists
alpha
active
Prior art date
Application number
ITMI940506A
Other languages
Italian (it)
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Boi
Testa Rodolfo
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of ITMI940506A0 publication Critical patent/ITMI940506A0/en
Priority to ITMI940506A priority Critical patent/IT1270993B/en
Priority to IL11302495A priority patent/IL113024A/en
Priority to DK95911342T priority patent/DK0750614T3/en
Priority to EP95911342A priority patent/EP0750614B1/en
Priority to PT95911342T priority patent/PT750614E/en
Priority to AU18948/95A priority patent/AU1894895A/en
Priority to JP52437095A priority patent/JP3683911B2/en
Priority to US08/716,160 priority patent/US5798362A/en
Priority to DE69521037T priority patent/DE69521037T2/en
Priority to PCT/EP1995/001001 priority patent/WO1995025726A1/en
Priority to ZA952208A priority patent/ZA952208B/en
Priority to ES95911342T priority patent/ES2158938T3/en
Priority to SI9530495T priority patent/SI0750614T1/en
Priority to AT95911342T priority patent/ATE201400T1/en
Priority to TW084105132A priority patent/TW416951B/en
Publication of ITMI940506A1 publication Critical patent/ITMI940506A1/en
Application granted granted Critical
Publication of IT1270993B publication Critical patent/IT1270993B/en
Priority to GR20010401292T priority patent/GR3036443T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Vengono descritti nuovi derivati chinazolilaminici efficaci nel bloccare i recettori ?1-adrenergici. Questi composti possono essere utilizzati quali utili agenti terapeutici per il trattamento delle malattie ed affezioni implicanti un'iperattività del sistema ?-adrenergico quali, ad esempio, l'ipertensione arteriosa e l'iperplasia prostatica benigna (BPH). Vengono inoltre descritti i metodi di preparazione di tali composti.New quinazolylamin derivatives are described that are effective in blocking? 1-adrenergic receptors. These compounds can be used as useful therapeutic agents for the treatment of diseases and diseases involving hyperactivity of the? -Adrenergic system such as, for example, arterial hypertension and benign prostatic hyperplasia (BPH). The methods of preparing these compounds are also described.

ITMI940506A 1994-03-18 1994-03-18 ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS IT1270993B (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITMI940506A IT1270993B (en) 1994-03-18 1994-03-18 ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS
DE69521037T DE69521037T2 (en) 1994-03-18 1995-03-17 CHINAZOLINYLAMINO DERIVATIVES WITH ALFA ANTAGONIST EFFECT
ZA952208A ZA952208B (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having alpha-antagonist activity
EP95911342A EP0750614B1 (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having alpha-antagonist activity
PT95911342T PT750614E (en) 1994-03-18 1995-03-17 AMINO-KINAZOLINYL DERIVATIVES WHICH HAVE ALPHA ANTAGONIST ACTIVITY
AU18948/95A AU1894895A (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having alpha-antagonist activity
JP52437095A JP3683911B2 (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having α-antagonistic activity
US08/716,160 US5798362A (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having α-antagonist activity
IL11302495A IL113024A (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having alpha-antagonist activity their preparation and pharmaceutical compositions comprising them
PCT/EP1995/001001 WO1995025726A1 (en) 1994-03-18 1995-03-17 QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY
DK95911342T DK0750614T3 (en) 1994-03-18 1995-03-17 Quinazolinyl amino derivatives with alpha antagonist activity
ES95911342T ES2158938T3 (en) 1994-03-18 1995-03-17 AMINOQUINAZOLINE DERIVATIVES THAT HAVE ALFA-ANTAGONIST ACTIVITY.
SI9530495T SI0750614T1 (en) 1994-03-18 1995-03-17 Quinazolinyl-amino derivatives having alpha-antagonist activity
AT95911342T ATE201400T1 (en) 1994-03-18 1995-03-17 CHINAZOLINYLAMINO DERIVATIVES WITH ALFA ANTAGONIST EFFECT
TW084105132A TW416951B (en) 1994-03-18 1995-05-23 Quinazolinyl-amino derivatives having <alpha>-antagonist activity
GR20010401292T GR3036443T3 (en) 1994-03-18 2001-08-23 Quinazolinyl-amino derivatives having alpha-antagonist activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI940506A IT1270993B (en) 1994-03-18 1994-03-18 ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS

Publications (3)

Publication Number Publication Date
ITMI940506A0 ITMI940506A0 (en) 1994-03-18
ITMI940506A1 ITMI940506A1 (en) 1995-09-18
IT1270993B true IT1270993B (en) 1997-05-26

Family

ID=11368249

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI940506A IT1270993B (en) 1994-03-18 1994-03-18 ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS

Country Status (15)

Country Link
US (1) US5798362A (en)
EP (1) EP0750614B1 (en)
JP (1) JP3683911B2 (en)
AT (1) ATE201400T1 (en)
AU (1) AU1894895A (en)
DE (1) DE69521037T2 (en)
DK (1) DK0750614T3 (en)
ES (1) ES2158938T3 (en)
GR (1) GR3036443T3 (en)
IL (1) IL113024A (en)
IT (1) IT1270993B (en)
PT (1) PT750614E (en)
TW (1) TW416951B (en)
WO (1) WO1995025726A1 (en)
ZA (1) ZA952208B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747490A (en) * 1995-09-29 1998-05-05 Merck & Co., Inc. Alpha 1b adrenergic receptor antagonists
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
IT1286302B1 (en) * 1996-04-10 1998-07-08 Rotta Research Lab CHINAZOLINE-4-AMINO-2- (PIPERIDINO-1-IL-4-SUBSTITUTED) WITH ANTI-HYPERTENSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND USE
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof
IT1312310B1 (en) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION
ITMI20012060A1 (en) * 2001-10-05 2003-04-05 Recordati Chem Pharm NEW N-ACYLATED HETEROCYCLES
US7071197B2 (en) 2002-06-14 2006-07-04 Recordati S.A. N,N-disubstituted diazocycloalkanes
US20040058962A1 (en) * 2002-06-14 2004-03-25 Amedeo Leonardi Phenylalkylamines and pyridylalkylamines
US20040072839A1 (en) * 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
WO2005058823A1 (en) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
MX2014015933A (en) 2012-06-20 2015-07-17 Novartis Ag Complement pathway modulators and uses thereof.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE925468C (en) * 1941-08-13 1955-03-21 Hoechst Ag Process for the preparation of ª †, ª † -Diaryl-propyl-amines
GB679676A (en) * 1950-04-03 1952-09-24 Dow Chemical Co Improved method for the production of salts of aromatic-oxy-aliphatic carboxylic acids
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3663706A (en) * 1969-09-29 1972-05-16 Pfizer Use of 2,4-diaminoquinazolines as hypotensive agents
DE2143730A1 (en) * 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substd pyridines prepn - hypotensives, analgesics and inters
US4044136A (en) * 1972-09-09 1977-08-23 Pfizer Inc. Aminoquinazoline therapeutic agents
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4062844A (en) * 1976-09-20 1977-12-13 Pfizer Inc. Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines
FR2389614A1 (en) * 1977-05-05 1978-12-01 Synthelabo Antihypertensive 2,4-di:amino-quinazoline(s) - prepd. from a 2-halo-4-amino-quinazoline and a secondary amine
US4607034A (en) * 1979-10-29 1986-08-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinazoline derivatives and pharmaceutical composition thereof
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
CS236097B1 (en) * 1983-06-01 1985-05-15 Jan Koenig Acylderivatives of 2-piperazinochinazoline and method of their preparation
AT384218B (en) * 1985-12-04 1987-10-12 Gerot Pharmazeutika METHOD FOR PRODUCING NEW CHINAZOLINE DERIVATIVES
US5110927A (en) * 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action

Also Published As

Publication number Publication date
ITMI940506A0 (en) 1994-03-18
GR3036443T3 (en) 2001-11-30
JPH09511238A (en) 1997-11-11
EP0750614B1 (en) 2001-05-23
TW416951B (en) 2001-01-01
PT750614E (en) 2001-10-31
DK0750614T3 (en) 2001-09-10
EP0750614A1 (en) 1997-01-02
ATE201400T1 (en) 2001-06-15
JP3683911B2 (en) 2005-08-17
ES2158938T3 (en) 2001-09-16
ZA952208B (en) 1995-12-28
DE69521037T2 (en) 2001-10-25
IL113024A (en) 2000-07-26
DE69521037D1 (en) 2001-06-28
AU1894895A (en) 1995-10-09
ITMI940506A1 (en) 1995-09-18
WO1995025726A1 (en) 1995-09-28
IL113024A0 (en) 1995-06-29
US5798362A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
IT1270993B (en) ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS
DK1039912T3 (en) Angiostatic agents and preparations for the treatment of GLC1A glaucoma
EA200000220A1 (en) COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND
TR199901172T2 (en) Newly substituted pyrazole derivatives.
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer&#39;s.
DK0943328T3 (en) Combination therapy for prophylaxis and / or treatment of benign prostatic hyperplasia
IS4972A (en) Use of the chelating agent clioquinol in the manufacture of a pharmaceutical composition for the treatment of Alzheimer&#39;s disease
TR199901604T2 (en) Quinoline and quinazoline compounds useful in treatment.
ATE212351T1 (en) ANDROSTENE DERIVATIVES
FI931765A7 (en) Steroid derivatives for the treatment of benign prostatic hyperplasia, their preparation and uses
MY128558A (en) Antipsoriatic nail polish
NO972391L (en) 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and their preparations and methods
ES2051733T3 (en) PROCEDURE FOR OBTAINING A TAMOXIFEN BASED MEDICINE FOR LOCAL USE.
DE59705562D1 (en) 7ALPHA- (5-METHYLAMINOPENTYL) -ESTRATRIENE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 7ALPHA- (5-METHYLAMINOPENTYL) -ESTRATRIENE AND THE USE THEREOF FOR USE THEREOF
SE9603725D0 (en) New teatment
DK0556322T3 (en) Aminosulfonylurinstof-ACAT inhibitors
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DK0565296T3 (en) Use of melatonin in the manufacture of a drug for the treatment of benign prostatic hyperplasia
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
BG101126A (en) The use of muramylpeptide compounds
DE59101818D1 (en) Pharmaceutical preparation containing stigmasta-4-en-3-one and their use.
BR9203266A (en) COMPOUND, PHARMACEUTICAL FORMULATION, PROCESS TO INHIBIT 5ALFA-REDUCTASE, PROCESSES TO TREAT BENIGN PROSTATE HYPERPLASIA, SEBORRHEA AND ANDROGENIC ALOPECIA
FR2718965B1 (en) New therapeutic application of spiramycin.
TR199701613T1 (en) Melatonin agonists for the treatment of benign prostatic hyperplasia.
ITMI920850A0 (en) BENZOFURAN-IMIDAZOLES FOR USE AS AROMATISIA INHIBITORS 17,20-LIASINELLA RPOPHYLAXIS AND TREATMENT OF BREAST CANCER AND BENIGN PROSTATIC HYPERPLASIA

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970327